Discovery of Clinical Candidate 2-((2<i>S</i>,6<i>S</i>)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor
作者:Xiang-Yang Ye、Stephanie Y. Chen、Shung Wu、David S. Yoon、Haixia Wang、Zhenqiu Hong、Stephen P. O’Connor、Jun Li、James J. Li、Lawrence J. Kennedy、Steven J. Walker、Akbar Nayeem、Steven Sheriff、Daniel M. Camac、Vidyhashankar Ramamurthy、Paul E. Morin、Rachel Zebo、Joseph R. Taylor、Nathan N. Morgan、Randolph P. Ponticiello、Thomas Harrity、Atsu Apedo、Rajasree Golla、Ramakrishna Seethala、Mengmeng Wang、Timothy W. Harper、Bogdan G. Sleczka、Bin He、Mark Kirby、David K. Leahy、Jianqing Li、Ronald L. Hanson、Zhiwei Guo、Yi-Xin Li、John D. DiMarco、Raymond Scaringe、Brad Maxwell、Frederick Moulin、Joel C. Barrish、David A. Gordon、Jeffrey A. Robl
DOI:10.1021/acs.jmedchem.7b00211
日期:2017.6.22
BMS-816336 (6n-2), a hydroxy-substituted adamantyl acetamide, has been identified as a novel, potent inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme (IC50 3.0 nM) with >10000-fold selectivity over human 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). 6n-2 exhibits a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice. It
BMS-816336(6n-2)是一种羟基取代的金刚烷乙酰胺,已被鉴定为一种新型强效抗人11β-羟类固醇脱氢酶1型(11β-HSD1)酶(IC 50 3.0 nM)的抑制剂,其> 10000倍对2型人11β-羟基类固醇脱氢酶(11β-HSD2)的选择性。6n-2在食蟹猴(ED 50 0.12 mg / kg)和DIO小鼠中表现出强大的急性药效作用。口服生物利用度(%F在临床前物种中的范围为20%至72%),并具有较高的峰谷比和较短的人类半衰期的预测药代动力学特征。该ADME资料符合我们每日一次给药的选择标准,其目标是在给药后的前12小时内对11β-HSD1酶进行强力抑制,然后进行“抑制假期”,从而有可能激活下丘脑-垂体-肾上腺(HPA)轴可能会缓解。在1期临床研究中发现6n-2具有良好的耐受性,代表了2型糖尿病,代谢综合征和其他由糖皮质激素控制调节的人类疾病的潜在新疗法。